open access

Vol 2, No 2 (2011)
Case report
Published online: 2011-07-15
Get Citation

Effectiveness of minimal dose of lenalidomide in the treatment of relapsed plasma cell myeloma

Hanna Ciepłuch, Jan Maciej Zaucha
Hematologia 2011;2(2):204-208.

open access

Vol 2, No 2 (2011)
CASE REPORTS
Published online: 2011-07-15

Abstract

We present a case of 63 year-old lady in the second relapse of plasma cell myeloma, initially treated with cyclophosphamide, thalidomide, dexamethasone chemotherapy combined with high dose chemotherapy and autologous hematopoietic stem cell transplantation and bortezomib and dexamethasone in the first relapse afterwards, who developed a severe pancytopenia being on standard dose of lenalidomide, that was started in the second relapse. We were forced to minimalize the dose of lenalidomide to 5 mg every other day, administered with a standard dexamethasone dose, and supported with growth factors. Such a treatment was reasonably safe and produced complete response. The patient remains in complete remission on maintenance therapy with lenalidomide.
Hematologia 2011; 2, 2: 204–208

Abstract

We present a case of 63 year-old lady in the second relapse of plasma cell myeloma, initially treated with cyclophosphamide, thalidomide, dexamethasone chemotherapy combined with high dose chemotherapy and autologous hematopoietic stem cell transplantation and bortezomib and dexamethasone in the first relapse afterwards, who developed a severe pancytopenia being on standard dose of lenalidomide, that was started in the second relapse. We were forced to minimalize the dose of lenalidomide to 5 mg every other day, administered with a standard dexamethasone dose, and supported with growth factors. Such a treatment was reasonably safe and produced complete response. The patient remains in complete remission on maintenance therapy with lenalidomide.
Hematologia 2011; 2, 2: 204–208
Get Citation

Keywords

plasma cell myeloma; relapse; lenalidomide; maintenance therapy

About this article
Title

Effectiveness of minimal dose of lenalidomide in the treatment of relapsed plasma cell myeloma

Journal

Hematology in Clinical Practice

Issue

Vol 2, No 2 (2011)

Article type

Case report

Pages

204-208

Published online

2011-07-15

Bibliographic record

Hematologia 2011;2(2):204-208.

Keywords

plasma cell myeloma
relapse
lenalidomide
maintenance therapy

Authors

Hanna Ciepłuch
Jan Maciej Zaucha

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.